Wed, Mar 4, 2015, 7:24 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Celgene Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • bigkaboomba bigkaboomba Nov 12, 2012 10:29 PM Flag

    What CELGZ worth

    This analysis is good but requires some clarification as the sales royalties may be much larger than what is projected here. Below are the terms--please note the 10% above $3bn which is excluded. Also note that the royalties are extended 5 years (until 2030) as long as sales stay above $1 bil. I wrote here on 10/12/12 that my discounting lead me to believe that CELGZ was undervalued. Today I feel the it is AGAIN EVEN THOUGH IT DOUBLED. Why? Because I think there is a greater than 75 % chance that the trials pipeline will add several more platforms---melanoma, etc. I believe that prior approvals will get to $1bn + and so will Panc. So were at $2 BEFORE some very large markets likely will be added, and well before the "sunset". Should we reach $4bn--possible before 2020--then we could get $275mn annually for 10 years. That's $6.39 x 10 = $63.90 per CVR. Prior I expect that $2.5bn is easy by 2017 which would payout over $1 per CVR and climb---perhaps they payout $7 per CVR upto 2020. In total we could get more than $70 PLUS the $6.93 Panc milestone in return per CVR through 2030 if Abraxane is the blockbuster I believe it is. For the record I am sceptical that they will make the April 1 milestone---but maybe if someone kicks the FDA in the #$%$---not at all likely tho--. Regardless, approval and $6.93 is NOW 99% done and any discount to $7 is a BUY as my NPV is now $11.

    Milestone 2: $300m cash upon approval of ABRAXANE by FDA for pancreatic cancer with overall survival claim in US label

    o Milestone 3: $100m cash payment upon FDA approval of ABRAXANE for pancreatic cancer if approval comes by April 1, 2013

    o Milestone 4: Potential cash royalty payments upon achievement of certain ABRAXANE and nab-pipeline products net revenue

    § 2.5% of revenue between $1bn and $2bn
    § "additional" 5% of revenue between $2bn and $3bn
    § "additional" 10% of revenue above $3bn

3.24+0.01(+0.31%)Mar 4 3:39 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Wayfair Inc.
NYSEWed, Mar 4, 2015 4:02 PM EST
Veeva Systems Inc.
NYSEWed, Mar 4, 2015 4:02 PM EST